London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
discuss illegal or criminal activities.
post any confidential or price sensitive information or that is not public knowledge.
post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
post any personal details (e.g. email address or phone number).
post live price or level 2 updates.
publish content that is not your original work, or infringes the copyright or other rights of any third party.
post non-constructive, meaningless, one word (or short) non-sense posts.
post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
post any affiliate or referral links, or post anything asking for a referral.
post or otherwise publish any content unrelated to the board or the board's topic.
re-post premium share chat posts on regular share chat.
restrict or inhibit any other user from using the boards.
impersonate any person or entity, including any of our employees or representatives.
post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium and Verified Members
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Schrow and Nol " all we can say at this time is that targeting at home patients is not the optimal route for SNG and so therefore they have to push their resources into the hospitalized patients " I said this to pmjh when he was still with us in basecamp in December. He was on the Activ-2 trail long before anyone else and I think it took over all of his thinking. I put forward the simplistic view that if it worked in hospitals and we had 100k treatments in hand we'd do well to just send it in. Might still be proved wrong if Activ-2 somehow leads to an EUA but what the world surely needs first is to clear out the breathless/oxygen patients in its hopsitals. You can't imagine any context in which india would be able to set up and run an at Home programme now - whereas patients could be on the aerogen treamtment sitting in hospital corridors - being treated straight away and coming back from the brink.
They’ve established the profile of at home patients who’d benefit the most from treatment - those exhibiting symptoms of breathlessness - so we now have a targeted treatment - so not ruling out home use
By saying that patient numbers were limiting the results was a shot in the foot really as we know that the hospital patients numbers were 102. Versus 120 at home ...
But all we can say at this time is that targeting at home patients is not the optimal route for SNG and so therefore they have to push their resources into the hospitalized patients Where they can show benefits over costs , imo
I don't think they were on a damage limiting exercise, I think they were just scientists talking science. Unfortunately, their presentational and commercial skills are not trained, spending their days in lab coats looking down microscopes.
And as is the case with Synairgen, they wanted to ensure the highest levels of integrity with respect to the data they were presenting and therefore made a point of emphasising (over-emphasising IMO) the limitations in the data simply due to patient numbers recruited.
Yes, a more optimistic tone should have been struck; 0 hospitalisations on drug vs 2 on placebo is, after, as good as we could have expected to do... but this was not the setting for that. There'll be more detailed catch ups with Richard in future.
The market did like the numbers anyway, hence the 10% bump in the morning, so I'm quite confident this is just a temporary blip in investor sentiment. And in any case, its hardly been the first of its kind!
Richard and the team seemed very disappointed in the home trial results and tried their best to find a silver lining ... The impression I got was they were on a damage limiting exercise orchestrated by savvy company advisors but that their hearts weren’t in the exercise ...
I believe that SNG will sign a partnership deal at some stage, but we will probably need the P3 results first ..
Interesting theory TLW, one I'd never even pondered. With the annual results coming up and us being in the middle of Activ-2 and a global P3 it seems a bit strange to leave everything half way through, but there may well be many goings-on behind the scenes particularly with the new dataset we've just received. I think we're still a couple of months away from having these talks so I'd be surprised if those talks were happening at this stage and not in the summer.
Having said that though, the hint that manufacturing was starting in the summer, the company vacancies spotted a while ago, the hiring of these top dogs, all seem to be pointing towards something monumental happening in the horizon and those things can't be planned and executed all at once, meaning they clearly know a big change at the company is imminent and are preparing for it, or they're putting the wheels in motion for when that time comes. With us in the middle of two trials at the moment, I might go with the latter.
Also MrCosts, I did note your moaning this week but it's been understandable. Good to have you back on board.
Like that thinking. RM has clearly said in the past that they are in contact with various potential partners for the future of SNG which will be necessary for its evolution. Their previous partnership with AZ alone means they have some knowledge and experience of how that might work, or look like. It would also be reasonable to pontificate that discussions (and possibly sharing of certain info/data within a NDA) have been on-going for some time. One thing for sure is that, the 'tickly bit' is near at hand .... so to speak and the SNG team must be permanently knackered, thus not always going to be on top form.
It was very good to hear that Richard Marsden has brought in three highly qualified and experienced specialists, presumably to advise and assist in the next phase, whether that be a takeover of the company, or licensing deals to bring about the production of the 100K doses per month quantities of SNG001 that were hinted at earlier this year. The team, who have diversified expertise and experience could well be taking part in complex takeover negotiations? Interestingly, the last time I was invested in a company that was taken over, the announcement came at the same time as the company's annual results. Someone mentioned earlier that Mr. Marsden wasn't his usual ebullient self during the recent webinar. Professor Wilkinson and Professor Francis also appeared to be somewhat under par. It could of course be that all three were very tired following an intensive work schedule? An alternative explanation might be that all three were aware of an imminent major change in the near future? I am speculating far too much, and will leave it there for the time being.
Regards, and best wishes to all genuine Synairgen investors.